Abituzumab（阿比妥珠單抗）是一種人源化抗整合素αV單克隆抗體(IgG2型)。Abituzumab可有效降低FAK、Akt和ERK的磷酸化。阿比妥珠單抗可用于癌癥研究,尤其是前列腺癌

貨號(hào)：DHC21901

產(chǎn)品鏈接：http://www.antibodysystem.com/product/188.html

寄主物種：Human

形式：Liquid

存儲(chǔ)緩沖區(qū)：0.01M PBS, pH 7.4.

濃度：1 mg/ml

純度：>95% by SDS-PAGE.

克隆性：Monoclonal

應(yīng)用：Research Grade Biosimilar

介紹：Abituzumab是一種人源化抗 integrin αV 單克隆抗體 (IgG2 型)。Abituzumab 能有效減少 FAK、 Akt 和 ERK 的磷酸化。Abituzumab 可用于癌癥，尤其是前列腺癌的研究。

儲(chǔ)存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

聯(lián)系方式：027-65279366

參考文獻(xiàn)：

Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression. PMID: 28314844
STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease. PMID: 33004536
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. PMID: 25319061
Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer. PMID: 26839144
Integrins as A New Target for Cancer Treatment. PMID: 30451118
Integration of NMR Spectroscopy in an Analytical Workflow to Evaluate the Effects of Oxidative Stress on Abituzumab: Beyond the Fingerprint of mAbs. PMID: 37278511
Integrin Inhibitors in Prostate Cancer. PMID: 29415418
Integrins as Therapeutic Targets: Successes and Cancers. PMID: 28832494
A novel therapeutic option for castration-resistant prostate cancer: after or before chemotherapy? PMID: 23838638
Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. PMID: 29893938
Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. PMID: 20031203
Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses. PMID: 24242902
A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy. PMID: 23791392

Abituzumab(DI17E6)(0.01、0.1、1、10、30100μg/mL；24小時(shí))抑制PCa細(xì)胞與多種細(xì)胞外基質(zhì)蛋白的粘附,但不抑制I型膠原[1]。Abituzumab(100μg/mL；12、18小時(shí))抑制了PCa細(xì)胞的運(yùn)動(dòng)和侵襲[1]。Abituzumab(0.01、0.1、1、10、30100μg/mL；24小時(shí))抑制PCa細(xì)胞粘附成骨細(xì)胞和骨基質(zhì)細(xì)胞系的能力[1]。Abituzumab(100μg/mL；24小時(shí))阻斷PCa癌細(xì)胞系中整合素介導(dǎo)的細(xì)胞信號(hào)[1]。細(xì)胞活力測(cè)定[1]細(xì)胞系：PCa細(xì)胞濃度：0.01、0.1、1、10、30100μg/mL培養(yǎng)時(shí)間：24小時(shí)結(jié)果：促進(jìn)PCa細(xì)胞從玻璃體凝集素(高達(dá)約20%的細(xì)胞以100μg/mL的速度脫落)、骨橋蛋白(高達(dá)大約10%的細(xì)胞以100ug/mL的速度分離)和纖維連接蛋白(高約10%的細(xì)胞在100μg/mL的速度剝離)上脫落,但不從I型膠原上脫落。細(xì)胞侵襲試驗(yàn)[1]細(xì)胞株：PCa細(xì)胞濃度：100μg/mL培養(yǎng)時(shí)間：12,18小時(shí)結(jié)果：與載體相比,侵襲能力被抑制了約25至30%,運(yùn)動(dòng)能力被抑制約30至40%。細(xì)胞活力測(cè)定[1]細(xì)胞系：PCa、hFOB、Saos2、HS-5、HDMEC細(xì)胞濃度：0.01、0.1、1、10、30100μg/mL培養(yǎng)時(shí)間：24小時(shí)結(jié)果：抑制PCa細(xì)胞與人成骨細(xì)胞系hFOB和Saos2以及骨髓基質(zhì)細(xì)胞系HS-5的粘附。促進(jìn)PCa細(xì)胞從αv整合素的已知表達(dá)者HDMEC中分離。Western Blot分析[1]細(xì)胞株：PC3、DU145、C4-2B、LNCaP、ARCaP和VCaP細(xì)胞濃度：100μg/mL培養(yǎng)時(shí)間：24小時(shí)結(jié)果：抑制了C4-2B和LNCaP分別在12小時(shí)和6小時(shí)開(kāi)始的FAK磷酸化；C4-2B和LNCaP分別在3小時(shí)和2小時(shí)開(kāi)始AKT磷酸化；和ERK磷酸化分別在C4-2B和LNCaP的1小時(shí)和1.5小時(shí)開(kāi)始。

[1].?Jiang Y, et al. Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression. Mol Cancer Res. 2017 Jul;15(7):875-883